MeSH D015270 - mycobacterium avium-intracellulare infection
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Lupin Research | Rifabutin | Rifabutin |  | 2014-02-24 |  |  |
| Novartis | Clofazimine | Lamprene |  | 1986-12-15 |  |  |
| Novitium Pharma | Rifabutin | Rifabutin |  | 2021-12-17 |  |  |
| Pfizer | Rifabutin | Mycobutin |  | 1992-12-23 |  |  |
| RedHill Biopharma | Amoxicillin, Omeprazole, Rifabutin | Talicia | 2034-02-12 | 2019-11-01 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
33%2/6
Phase 2
33%5/15
Phase 3
63%5/8
Approved: 2Overall Success rate: 7%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use